✦ LIBER ✦

Pegeinterferon alfa-2a (40 KD) (Pegasys) plus ribavirin (copegus) is an efficacious and safe treatment for chronic hepatitis C (CHC) in patients with compensated cirrhosis

✍ Scribed by P. Marcellin; S. Brillanti; H. Cheinquer; W.G.E. Cooksley; M.L. Shiffman; W.E. Schmidt; M. Brunda

Book ID: 117372673
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 125 KB
Volume: 38
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(03)80796-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PEG-IFN alfa-2a (40kd) (Pegasys) plus am

PEG-IFN alfa-2a (40kd) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naïve patients with chronic hepatitis C (CHC)

✍ G. Ideo; A. Attili; G. Ruggiero; A. Craxi; G. Di Perri; A. Mangia; A. Picciotto; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Predictors of virologic relapse in patie

Predictors of virologic relapse in patients with chronic hepatitis C (CHC) treated with peginterferon alfa-2a (40KD) (pegasys) alone or in combination with ribavirin (copegus)

✍ V. Balan; S. Zeuzem; H. Sette; M. Fried; D. Jensen; G. Pastore; P. Marcellin; F. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Treatment of patients with chronic hepat

Treatment of patients with chronic hepatitis C (CHC) with peginterferon alfa-2a (40KD) (Pegasys) alone or in combination with ribavirin (copegus) results in long-lasting sustained virological response

✍ M. Swain; M.-Y. Lai; M.L. Shiffman; W.G. Cooksley; A. Abergel; M. Diago; M. Brun 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 159 KB

Efficacy and safety of peginterferon alf

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

✍ Savino Bruno; Mitchell L. Shiffman; Stuart K. Roberts; Edward J. Gane; Diethelm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 500 KB 👁 1 views

The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40 KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis

503 Early prediction of sustained virolo

503 Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with chronic hepatitis C (CHC) and persistently normal alanine aminotransferase (ALT) levels

✍ P.J. Pockros; M. Diago; E. Gane; K.R. Reddy; D. Prati; M.L. Shiffman; P. Farci; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 65 KB

454 PREDICTIVE FACTORS OF THROMBOCYTOPEN

454 PREDICTIVE FACTORS OF THROMBOCYTOPENIA IN TREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN

✍ S. Mauss; A. Schober; T. Lutz; G. Moog; M. Schuchmann; R. Heyne; C. John; W. Sch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 152 KB